Biostage Inc. (BSTG)
Biostage to Host Investor Call
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing the technology to regenerate...
Biostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal Disease
HOLLISTON, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) (“Biostage” or the “Company”), a clinical-stage biotechnology company...
Biostage Appoints Ron Packard to Board of Directors
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company...
Biostage Announces $6 Million Financing to Advance Clinical Trial
HOLLISTON, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company...
Biostage Announces Chairman and CEO Transition
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments...
Regenerative medicine developer Biostage scraps Nasdaq uplisting, offering
Regenerative medicine developer Biostage (BSTG) has scrapped plans for an uplisting and accompanying public offering. Read more here.
Biostage Amends CEO Employment Agreement
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments...
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments...
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience...
Biostage Reports Corporate Highlights and Third Quarter Financial Results
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Biostage Schedules Conference Call and Webcast for Q3 2022 Results
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...
Biostage Announces Appointment of New Chief Financial Officer
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in...
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal...
Biostage Reports Q3 2021 Financial Results
/PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a bioengineering company developing next-generation esophageal implants based its...
Biostage Reports Q2 2021 Financial Results
HOLLISTON, Mass., Aug. 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ('Biostage' or the 'Company'), a bioengineering company developing ne...
Biostage Reports Q2 2021 Financial Results
Biostage Reports Q1 2021 Financial Results
HOLLISTON, Mass., May 24, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ('Biostage' or the 'Company'), a bioengineering company developing nex...
Biostage Reports Q1 2021 Financial Results
Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
HOLLISTON, Mass., April 13, 2021 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ('Biostage' or the 'Company'), a biotechnology company developing ne...
Biostage Reports 2020 Financial Results and Appointment of Interim Vice President of Finance
Biostage Strengthens Board of Directors with Appointment of Herman Sanchez
Biostage Reports Third Quarter 2020 Financial Results
HOLLISTON, Mass., Nov. 13, 2020 /PRNewswire/ -- Biostage, Inc. (OTCQB: BSTG) ('Biostage' or the 'Company'), a clinical-stage biotechnology company...
Biostage Reports Third Quarter 2020 Financial Results
Biostage Reports Second Quarter 2020 Financial Results
Biostage Reports First Quarter 2020 Financial Results
Biostage Reports First Quarter 2020 Financial Results
Biostage Reports 2019 Financial Results
Biostage Reports 2019 Financial Results
FDA OKs Biostage's IND for Cellspan Esophageal Implant
The FDA has approved Biostage's (OTC:BSTG) IND application for the Cellspan Esophageal Implant (CEI) to treat patients with end-stage esophageal disease that require a segmental surgical rese